Skip to main content
Sign In

You have reached the Web site for the Department of Pathology at the University of Colorado Denver.

Pathology Banner Image

Bolin Liu, MD

Associate Professor


  • MD, Beijing Medical University, Beijing, China (1987)
  • MS, Institute of Hematology, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Tianjin, China (1994)

Postdoctoral Education:

  • Postdoctoral Fellow Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center (UTMDACC), Houston, TX (1998-2001)
  • Visiting Scientist Department of Surgical Oncology, UTMDACC, Houston, TX (1994-1998) 

Research Activities:

  • ErbB receptor tyrosine kinase-mediated cell signaling in breast cancer
  • Epigenetic potentiation of chemotherapy in cancer treatment
  • View Research Page​

Selected Publications:

  • Huang, X.P., Gao, L., Wang, S., McManaman, J.L., Thor, A.D., Yang, X., Esteva, F.J., and Liu, B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Herceptin. Cancer Research 70(3):1204-1214, 2010
  • Lee, C-K., Wang, S., Huang, X., Ryder, J., and Liu, B. HDAC Inhibition Synergistically Enhances Alkylator-induced DNA Damage Responses and Apoptosis in Multiple Myeloma Cells. Cancer Letters 296: 233-240, 2010
  • Wang, S., Huang, X., Lee, C-K., and Liu, B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 29: 4225–4236, 2010
  • Huang, X., Wang, S., Lee, C-K., Yang, X., and Liu, B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Letters 2011 Aug 1;307(1):72-9.​
  • Ma J, Wang S, Zhao M, Deng XS, Lee CK, Yu XD, Liu B. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer 2011 Jun 16;11(1):255.
  • Liu, B.*, Fan, Z., Edgerton, S.M., Yang, X., Lind, S.E., and Thor, A.D.* Potent Anti-proliferative Effects of Metformin on Trastuzumab-resistant Breast Cancer Cells via Inhibition of ErbB2/IGF-1 Receptor Interactions. Cell Cycle    Sep 1, 10 (17): 2959-2966, 2011 *Corresponding authors
  • Cai, B., Wang, S., Huang, J., Lee, C-K., Gao, C., and Liu, B. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. American Journal of Translational Research 2013; 5(1):36-46.
  • Wang, L., Huang, Z., Lin H., Li, Z., Hetzel, F.W., and Liu, B. Effects of photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. Photodiagnosis and Photodynamic Therapy, 2013  

  • Wang, S., Huang, J., Lyu, H., Lee, C-K., Tan, J., Wang, J., and Liu, B. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease (2013) 4, e556; doi:10.1038/cddis.2013.79

  • Cai, B., Lyu, H., Huang, J., Wang, S., Lee, C-K., Gao, C., and Liu, B. Combination of Bendamustine and Entinostat Synergistically Inhibits Proliferation of Multiple Myeloma Cells via Induction of Apoptosis and DNA Damage Response. Cancer Letters 2013; 335 (2): 343-350.

  • Wahdan-Alaswad, R. and Liu, B. “Sister” miRNAs in cancers. Cell Cycle 2013; 12 (24): 3703-3704; December 15, 2013

  • Wang, S., Huang, J., Lyu, H., Cai, B., Yang, X., Li, F., Tan, J., Edgerton, S.M., Thor, A.D., Lee, C-K., and Liu, B. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Research 2013; 15:R101. doi:10.1186/bcr3563

  • Huang, J., Wang, S., Lyu, H., Cai, B., Yang, X., Wang, J., and Liu, B. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Molecular Cancer 2013; 12:134 doi:10.1186/1476-4598-12-134

  • Wahdan-Alaswad, R., Fan, Z., Edgerton, S.M., Liu, B., Deng, X-S., Arnadottir, S.S., Richer, J.K., Anderson, S.M., and Thor, A.D.  Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 12(24): 3759-3769; December 15, 2013

  • Milgroom, A., Intrator, M., Madhavan, K., Mazzaro, L., Shandas, R., Liu, B., and Park, D. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloids Surf. B: Biointerfaces 2014 Apr 1; 116:652-7

  •  Lee, Y., Ma, J., Lyu, H., Huang, J., Kim, A., and Liu, B. Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochim Biophys Sin 2014, 46: 190–198

  • Ma, J., Lyu, H., Huang, J., and Liu, B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Molecular Cancer 2014, 13:105

  • Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton SM, Williams LL, Thor AD, Yang X. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila). 2014; 7(2):199-210

Office Location:

 Research Center 1 South

 Room 5118




 Office Phone:



(303) 724-3749

(303) 724-3750

(303) 724-3712


Mailing Address:

 University of Colorado Anschutz Medical Campus

 12801 East 17th Avenue

 Mail Stop 8104

 Aurora, CO 80045​​​​